



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: CLARK, Abbot F., et al.

Serial No: 10/658,986 (Conf #6064)

Filed: 10 September 2003

Examiner:

Group Art Unit:

FOR: Methods For Diagnosing Glaucoma And Discovering Anti-Glaucoma Drugs

**INFORMATION DISCLOSURE STATEMENT PURSUANT  
TO 37 C.F.R. 1.56, 1.97, AND 1.98**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. 1.56, 1.97, and 1.98, Applicants submit the patents, articles, and other information referenced in the specification as filed. The references are listed on the attached PTO Form 1449.

Applicants request that the listed patents, articles, and other information be considered during prosecution of this application and that they appear among the "References Cited" on any patent issuing herefrom.

Respectfully submitted,

10 Feb. 2004

Date

By:

Teresa J. Schultz

Teresa J. Schultz

Registration No. 40,256

817-551-4231

Address for Correspondence:

Alcon Research, Ltd.  
Attn: Teresa J. Schultz  
6201 S. Freeway, Mail Code Q-148  
Fort Worth, TX 76134-2099

Attorney Docket No.: 1581 US FA



PTO/SB/08A (04-03)

Approved for use through 04/30/2003; OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Complete if Known**

Substitute for form 1449/PTO					
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>					
Sheet	1	of	3	Attorney Docket Number	1581 US FA

**U. S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> ( <i>if known</i> )			
A1	US-				
A2	US-				
A3	US-				
A4	US-				
A5	US-				
A6	US-				
A7	US-				
A8	US-				
A9	US-				
A10	US-				
A11	US-				
A12	US-				
A13	US-				
A14	US-				
A15	US-				
A16	US-				
A17	US-				
A18	US-				
A19	US-				

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> ( <i>if known</i> )				
A20		AU 728438	04/26/2001	Clark et al.		
A21		WO 96/14411 A1	05/17/1996	University of California		
A22		WO 96/33287 A1	10/24/1996	Institut National De La Rec		
A23		WO 98/24932 A1	06/11/1998	Clark et al.		
A24						
A25						

Examiner Signature		Date Considered
--------------------	--	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**Complete if Known****INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

2

of

3

**Application Number**

10/658,986 (Conf #6064)

**Filing Date**

10 September 2003

**First Named Inventor**

CLARK, Abbot F., et al.

**Art Unit****Examiner Name**

1581 US FA

<b>NON PATENT LITERATURE DOCUMENTS</b>			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	B1	Bamberger, et al., The Journal of Clinical Investigation, "Glucocorticoid Receptor $\beta$ , a Potential endogenous Inhibitor of Glucocorticoid Action in Humans," 95:2435-2441, 1995	
	B2	Caskey, C.T., J.A.M.A., "Molecular Medicine. A Spin-off From the Helix," 269:15, 1986-1992, 1993	
	B3	Clark, A.F. Journal of Glaucoma, "Steroids, Ocular Hypertension, and Glaucoma", 4:354-369, 1995	
	B4	Cummings, Michael R., Human Heredity, Fourth Edition, 1997	
	B5	Encio, et al., Journal of Biological Chemistry, "The Genomic Structure of the Human Glucocorticoid Receptor," 266(11):7182-7188, 1991	
	B6	Giguère et al., "Functional Domains of the Human Glucocorticoid Receptor," Cell, 46:645-652, 1986	
	B7	Hernandez, et al., Invest. Ophthalmol. Vis. Sci., "Glucocorticoid Target Cells in Human Outflow Pathway: Autopsy and Surgical Specimens," 24:1612-1616, 1983	
	B8	Hollenberg et al., "Primary structure and expression of a functional human glucocorticoid receptor cDNA," Nature, 318:635-641, 1985	
	B9	Jorde, et al., Medical Genetics, Second Edition, 1999	
	B10	Leung, et al., "Association of Glucocorticoid Insensitivity with Increased Expression of Glucocorticoid Receptor $\beta$ ," Journal of Experimental Medicine, 186(9):1567-1574, 1997	


Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (04-03)

Approved for use through 04/30/2003, OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

**Complete if Known**

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

3

of

3

Application Number

10/658,986 (Conf #6064)

Filing Date

10 September 2003

First Named Inventor

CLARK, Abbot F., et al.

Art Unit

Examiner Name

Attorney Docket Number

1581 US FA

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C1	Myers, R.M., et al., "Detection of DNA Variation", Genome Analysis, Birren (eds) 2:287-384, 1998	
	C2	Oakley et al., "Expression and Subcellular Distribution of the $\beta$ -Isoform of the Human Glucocorticoid Receptor," Endocrinology, 138(11):5028-5038, 1997	
	C3	Oakley, et al., The Journal of Biological Chemistry, "The Human Glucocorticoid Receptor $\beta$ Isoform," 271:16, 9550-9559, 1996	
	C4	Strachan, et al., Human Molecular Genetics, 367-399, 1996	
	C5	Weinreb, et al., Invest. Ophthalmol. Vis. Sci., "Detection of Glucocorticoid Receptors in Cultured Human Trabecular Cells," 21:3, 403-407, 1981	
	C6	Wordinger, et al., "Effects of Glucocorticoids on the Trabecular Meshwork: Towards a Better Understanding of Glaucoma," Progress in Retinal and Eye Research, 18(5):629-667, 1999	
	C7		
	C8		
	C9		
	C10		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.